Esophagectomy for patients with resectable esophageal cancer and cervical lymph node metastases

Gepubliceerd: 01-05-2014 Laatst bijgewerkt: 19-03-2025

Transthoracic esophageal resection combined with three field lymphadenectomy for patients with esophageal cancer and proven cervical lymph node metastasis is feasible and safe and might result in better survival rates.

Ethische beoordeling	Niet van toepassing
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON24304

Bron
Nationaal Trial Register

Verkorte titel
EPIC

Aandoening

Esophageal cancer; Cervical lymph node metastasis

Ondersteuning

Primaire sponsor: University Medical Center Utrecht
Overige ondersteuning: initiator

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Primary outcome is the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC).

Toelichting onderzoek

Achtergrond van het onderzoek

Rationale: There is no world wide consensus on the oncological benefit versus increased morbidity associated with three field lymphadenectomy in patients with esophageal cancer and cervical lymph node metastases. In Asian countries, esophagectomy is commonly combined with a three field lymphadenectomy, including resection of cervical, thoracic and abdominal lymph nodes. However, in Western countries patients with cervical lymph node metastases are generally precluded from curative treatment.

Objective: To assess the safety and feasibility of curative esophagectomy combined with three field lymphadenectomy after chemo-radiation in Western patients with resectable thoracic esophageal carcinoma and cervical lymph node metastases.
Secondary objective is to determine the effect on survival and recurrence.

Study design: Mono centre prospective single-arm feasibility trial.

Study population: Western patients diagnosed with resectable (cT1-4a, N0-3) intra thoracic esophageal carcinoma with histological or cytological proven cervical lymph node metastases.

Intervention: Transthoracic esophageal resection combined with three field lymphadenectomy.

Main study parameters/ endpoints: Primary outcome is the percentage of overall complications grade 3b and higher as stated by the Modified Clavien-Dindo classification. Secondary outcomes are mortality, operation related events and postoperative recovery, disease free survival, overall survival and if applicable the location of recurrent disease.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The additional burden for the patient consists of an esophagectomy combined with three field lymph node dissection including thoracic, abdominal, and bilateral cervial level II, II, and IV (parajugular and posterior triangle) lymph node dissection. Pre-operative evaluation will be performed according to general practice. Postoperative care and outpatient visits do not differ from regular protocol. The study is associated with a high risk classification. As there is a potential survival benefit, we consider the additional burden and risks justified. This study is designed as a one group study, which eliminates group relatedness.

Doel van het onderzoek

Transthoracic esophageal resection combined with three field lymphadenectomy for patients with esophageal cancer and proven cervical lymph node metastasis is feasible and safe and might result in better survival rates.

Onderzoeksopzet

- Peri-operative

- Post-operative during hospital admission

- During follow up period of 5 years. (fist year post surgery every 3 months, second year every 6 months, third, fourth and fifth year once every year)

Onderzoeksproduct en/of interventie

Transthoracic esophageal resection combined with three field lymphadenectomy.

Contactpersonen

Publiek

Department of Surgery, G04.228
University Medical Center Utrecht
S. Horst, van der
Heidelberglaan 100, 3584 CX Utrecht
Utrecht
The Netherlands
+31 (0)88 755 8074 pager 3479

Wetenschappelijk

Department of Surgery, G04.228
University Medical Center Utrecht
S. Horst, van der
Heidelberglaan 100, 3584 CX Utrecht
Utrecht
The Netherlands
+31 (0)88 755 8074 pager 3479

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

-Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus.

-Surgical resectable carcinoma (T1-4a, N0-3)

-Histologically/ cytologically proven resectable cervical lymph node metastases

-Age > 18 and < 80 years

-European Clinical Oncology Group (ECOG) performance status 0,1 or 2

-Written informed consent

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Distant metastases

- Inadequate pulmonary function disabling transthoracic resection

- Previous neck dissection

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blindering:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland
Status: Werving nog niet gestart

(Verwachte) startdatum:	01-09-2014
Aantal proefpersonen:	20
Type:	Verwachte startdatum

Ethische beoordeling

Niet van toepassing

Soort:	Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 44167
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL4430
NTR-old	NTR4552
CCMO	NL48231.041.14
OMON	NL-OMON44167

Resultaten